Delisting riskPopularity #4,337
GRI Bio (GRI)
Develops NKT-cell therapies for pulmonary fibrosis and autoimmune disease.
$2.08
vs last close+0.03 (+1.46%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | 104.17% | 93.6K shares | |
|---|---|---|---|
| 11 holders · as of Jun 30, 2026 | |||
| Adds to | 104.17% | ||
89.8K company shares as of Sep 2, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Two share counts disagree (2.19M in the company's Sep 23, 2026 report, 89.8K elsewhere); stakes use the report.
These groups come from separate filings that can overlap, so they add to 104.17%; nothing is left for Other.
13F, as of Jun 30, 2026
11 holders · 93.6K shares · 6 new positions · 7 increased · 2 reduced · 1 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| HRT Financial LP | 28.8K | 32.04% | +28.8Knew | Aug 14, 2026 |
| Vanguard Capital Management LLC | 21.4K | 23.79% | +21.4Knew | Aug 13, 2026 |
| Geode Capital Management, LLC | 13.9K | 15.44% | −4.6K | Aug 12, 2026 |
| Citadel Advisors LLC | 13.4K | 14.89% | +13.4Knew | Sep 2, 2026 |
| Morgan Stanley | 8.7K | 9.73% | +8.7Knew | Aug 13, 2026 |
| UBS Group AG | 4.9K | 5.48% | −3.8K | Aug 13, 2026 |
| Tower Research Capital LLC (TRC) | 2.4K | 2.71% | +1.4K | Aug 11, 2026 |
| Barclays PLC | 83 | 0.09% | +83new | Aug 14, 2026 |
13D/G · 5% or more, as filed
No 13D/G filer at 5% or more on record.
Form 4
Latest trades
Nothing filed in the last 12 months.
House and Senate disclosures
Not reported.